Sector: Life Sciences

Latest content

Janssen sues Amgen as new wave of biosimilar disputes starts

A lull in BPCIA litigation has now come to an end

07 December 2022

Brazilian Supreme Court gives hope to companies facing shortened patent terms

Patentees may be able to avoid the loss of exclusivity created by another recent top court decision

06 December 2022

Merck’s $1.35 billion purchase is the latest deal driven by patent cliff fears

Imago BioSciences buyout is intended to diversify the company’s revenue streams

28 November 2022

US Supreme Court to review a false dichotomy in Amgen v Sanofi

Saturday Opinion: In its petition for certiorari, Amgen painted a picture of a Federal Circuit run amok. However, the dichotomy presented by Amgen in its petition for certiorari is a false one

26 November 2022

AbbVie’s Imbruvica victory at Federal Circuit adds to Humira successes

The company’s latest win means that its second highest selling drug will not face US competition for a decade

22 November 2022

US Federal Trade Commission set to tighten screws on patent strategies

New policy statement likely to target pay-for-delay deals and sham litigation

18 November 2022

Revealed: US filing trends, patent verdicts and competitor litigation detente

The second instalment of the joint IAM-Docket Navigator US litigation report focuses on the most contentious technology centres in 2022’s third quarter

18 November 2022

Your guide to synthetic drug royalty dealmaking

Selling revenue streams is an increasingly important way of monetising pharma innovations

16 November 2022

Why Germany is opposing the WTO’s decision to suspend patent protection

While WTO member states have expressed general sympathy for the goal to provide broad access to vaccine technology during the pandemic, Germany continues to favour patent protection over compulsory licensing.

16 November 2022

Regeneron’s lightning-fast patent trial to reshape originator-v-biosimilar litigation strategies

District Court decision could mean plaintiffs have more power to control speed and scope of US litigation

14 November 2022

Unlock unlimited access to all IAM content